Blood Biomarkers for Neurodegeneration

Clinical MedicineUpdated Aug 18, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

3 papers

Active filtersClassification:Supporting

Showing 1-3 of total 3 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2021CrossrefSupporting evidence267 citations

2016OpenAlexSupporting evidence751 citations

Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa

Jens Kühle; Christian Barro; Ulf Andréasson; Tobias Derfuß; Raija L.P. Lindberg; Åsa Sandelius; Victor Liman; Niklas Norgren; Kaj Blennow; Henrik Zetterberg

Apr 12, 2016Clinical Chemistry and Laboratory Medicine (CCLM)

2016OpenAlexSupporting evidence363 citations

CXCL13 is a plasma biomarker of germinal center activity

Colin Havenar‐Daughton; Madelene Lindqvist; Antje Heit; Jennifer E. Wu; Samantha Reiss; Kayla Kendric; Simon Bélanger; Sudhir Pai Kasturi; Elise Landais; Rama Akondy; Helen M. McGuire; Marcella Bothwell; Parsia A. Vagefi; Eileen P. Scully; IAVI Protocol C Principal Investigators; Georgia D. Tomaras; Mark M. Davis; Pascal Poignard; Rafi Ahmed; Bruce D. Walker; Bali Pulendran; M. Juliana McElrath; Daniel E. Kaufmann; Shane Crotty; Matt A. Price; Jill Gilmour; Pat Fast; Anatoli Kamali; Eduard J. Sanders; Omu Onzala; Susan Allen; Eric Hunter; Etienne Karita; William Kilembe; Shabir Lakhi; Mubiana Inambao

Feb 23, 2016Proceedings of the National Academy of Sciences

Evidence

Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration

Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa

CXCL13 is a plasma biomarker of germinal center activity